Grading of tumor regression in non-small cell lung cancer after neoadjuvant therapy

被引:0
|
作者
Junker, K
Thomas, M
Schulmann, K
Klinke, V
Bosse, U
Muller, KM
机构
[1] ST ELIZABETH HOSP,IBBENBUREN,GERMANY
[2] UNIV MUNSTER,MED KLIN A,D-4400 MUNSTER,GERMANY
[3] INST PATHOL,OSNABRUCK,GERMANY
来源
PATHOLOGE | 1997年 / 18卷 / 02期
关键词
non-small cell lung cancer; neoadjuvant therapy; therapy-induced tumor regression; spontaneous tumor regression; grading of tumor regression;
D O I
10.1007/s002920050201
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In the scope of a multi-center-study 35 resection specimens from patients with locally advanced non-small cell lung cancer after neoadjuvant chemotherapy and radiation were processed histologically and graded according to the following regression grading system: grade I: no or only slight, in general spontaneous tumor regression, grade II a: incomplete tumor regression with more than 10% and grade II b less than 10% vital tumor tissue as well as grade III: complete tumor regression. In 15 patients with grade II a to III tumor regression roughly concentric foci of various size with a sequence of central tumor necrosis, narrow foam cell rim, vascular granulation tissue and peripheral scar formation were demonstrated as characteristic feature of response to neoadjuvant therapy. In patients with grade II b to III tumor regression (''responders'') median survival time of 27.9 months was significantly longer than in patients with grade I to II a tumor regression (''non-responders'') with a median survival time of 12.7 months.
引用
收藏
页码:131 / 140
页数:10
相关论文
共 50 条
  • [21] Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy
    Liu-Jarin, XL
    Stoopler, MB
    Raftopoulos, H
    Ginsburg, M
    Gorenstein, L
    Borczuk, AC
    [J]. MODERN PATHOLOGY, 2003, 16 (11) : 1102 - 1108
  • [22] Neoadjuvant gefitinib therapy: a potential standard therapy for non-small cell lung cancer
    Nishida, Tomoki
    Saito, Yuichi
    Fukai, Ryuta
    [J]. JOURNAL OF THORACIC DISEASE, 2022, 14 (04) : 799 - 801
  • [23] Neoadjuvant chemotherapy in non-small cell lung cancer
    Niklinski, J
    [J]. 8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 217 - 223
  • [24] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
    Sanber, Khaled
    Rosner, Samuel
    Forde, Patrick M.
    Marrone, Kristen A.
    [J]. BIODRUGS, 2023, 37 (06) : 775 - 791
  • [25] Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
    Leal, Ticiana A.
    Ramalingam, Suresh S.
    [J]. CELL REPORTS MEDICINE, 2022, 3 (07)
  • [26] Neoadjuvant strategies for non-small cell lung cancer
    van Zandwijk, N
    [J]. LUNG CANCER, 2001, 34 : S145 - S150
  • [27] Neoadjuvant chemoradiation in non-small cell lung cancer
    Milleron, B.
    Girard, N.
    Gounant, V.
    Mornex, F.
    [J]. CANCER RADIOTHERAPIE, 2007, 11 (1-2): : 36 - 40
  • [28] Neoadjuvant chemotherapy for non-small cell lung cancer
    Pinder-Schenck, M.
    Bepler, G.
    [J]. MINERVA CHIRURGICA, 2009, 64 (06) : 611 - 628
  • [29] Neoadjuvant chemotherapy in non-small cell lung cancer
    Felip, E
    Rosell, R
    [J]. CURRENT MEDICINAL CHEMISTRY, 2002, 9 (08) : 893 - 898
  • [30] Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer
    Khaled Sanber
    Samuel Rosner
    Patrick M. Forde
    Kristen A. Marrone
    [J]. BioDrugs, 2023, 37 : 775 - 791